Protagonist Therapeutics, Inc.

NasdaqGM:PTGX Lagerbericht

Marktkapitalisierung: US$1.9b

Protagonist Therapeutics Management

Management Kriterienprüfungen 4/4

Protagonist Therapeutics' CEO ist Dinesh Patel , ernannt in Dec 2008, hat eine Amtszeit von 15.5 Jahren. Die jährliche Gesamtvergütung beträgt $7.07M , bestehend aus 9.3% Gehalt und 90.7% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.72% der Aktien des Unternehmens, im Wert von $14.43M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.4 Jahre bzw. 9.4 Jahre.

Wichtige Informationen

Dinesh Patel

Geschäftsführender

US$7.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts9.3%
Amtszeit als Geschäftsführer15.5yrs
Eigentum des Geschäftsführers0.7%
Durchschnittliche Amtszeit des Managements3.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder9.4yrs

Jüngste Management Updates

Recent updates

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Apr 13
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't

Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise

Feb 25

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Dec 28
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Jul 04
We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth

Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

Mar 20
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts

An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

Feb 06
An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued

We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Jun 15
We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate

Protagonist: Too Many Red Flags

Jun 08

Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

May 11
Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%

Protagonist Is Still Being Undervalued Like There's Real Risk

Feb 01

Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Jan 04
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Aug 06
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Jun 19
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year

Protagonist Therapeutics closes $132M capital raise

Jun 18

Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy

Jun 03

This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

May 21
This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet

Protagonist EPS beats by $0.03, beats on revenue

May 04

How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?

Feb 09
How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Dinesh Patel im Vergleich zu den Einnahmen von Protagonist Therapeutics verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2024n/an/a

US$162m

Dec 31 2023US$7mUS$655k

-US$79m

Sep 30 2023n/an/a

-US$140m

Jun 30 2023n/an/a

-US$138m

Mar 31 2023n/an/a

-US$140m

Dec 31 2022US$6mUS$630k

-US$127m

Sep 30 2022n/an/a

-US$130m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$122m

Dec 31 2021US$6mUS$600k

-US$126m

Sep 30 2021n/an/a

-US$108m

Jun 30 2021n/an/a

-US$81m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$2mUS$565k

-US$66m

Sep 30 2020n/an/a

-US$65m

Jun 30 2020n/an/a

-US$73m

Mar 31 2020n/an/a

-US$83m

Dec 31 2019US$2mUS$545k

-US$77m

Sep 30 2019n/an/a

-US$74m

Jun 30 2019n/an/a

-US$66m

Mar 31 2019n/an/a

-US$45m

Dec 31 2018US$4mUS$520k

-US$39m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$24m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$790kUS$475k

-US$37m

Vergütung im Vergleich zum Markt: DineshDie Gesamtvergütung ($USD7.07M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD5.64M).

Entschädigung vs. Einkommen: DineshDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Dinesh Patel (67 yo)

15.5yrs

Amtszeit

US$7,067,572

Vergütung

Dr. Dinesh V. Patel, Ph D., has been the Chief Executive Officer, President and Director at Protagonist Therapeutics, Inc. since December 2008 and serves as its Secretary. He served as Interim Chief Financ...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Dinesh Patel
CEO, President15.5yrsUS$7.07m0.71%
$ 13.5m
Asif Ali
Executive VP & Chief Financial Officer2.2yrsUS$1.40m0.0038%
$ 71.1k
Suneel Gupta
Chief Development Officer5.4yrsUS$2.22m0.25%
$ 4.8m
Mark Smythe
Founder & VP Technology3.4yrskeine Datenkeine Daten
Mohammad Masjedizadeh
Executive VP & Chief Technical Officer3.4yrskeine Datenkeine Daten
Matthew Gosling
Executive VP & General Counsel3.8yrskeine Datenkeine Daten
Carena Spivey
Head of HR & Senior VP of Human Resources3.4yrskeine Datenkeine Daten
Ashok Bhandari
Executive VP & Chief Drug Discovery and Preclinical Development Officer3.4yrskeine Datenkeine Daten
Carter King
Executive Vice President of Business Development3.2yrskeine Datenkeine Daten
Abha Bommireddi
Executive Vice President of Portfolio & Program Management3.4yrskeine Datenkeine Daten
Arturo Molina
Chief Medical Officer1.6yrskeine Daten0.0069%
$ 131.5k
Craig Ostroff
Interim Head of Regulatory Affairs & Advisorno datakeine Datenkeine Daten

3.4yrs

Durchschnittliche Betriebszugehörigkeit

59.5yo

Durchschnittliches Alter

Erfahrenes Management: PTGXDas Führungsteam des Unternehmens gilt als erfahren (3.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Dinesh Patel
CEO, President15.5yrsUS$7.07m0.71%
$ 13.5m
Harlan Weisman
Clinical Advisor9.4yrskeine Datenkeine Daten
Lewis Williams
Independent Director7yrsUS$351.52k0%
$ 0
Chaitan Khosla
Chairman of Scientific Advisory Board9.4yrsUS$188.07kkeine Daten
Harold Selick
Independent Chairman15.3yrsUS$395.27k0.048%
$ 903.1k
William Waddill
Independent Director7.9yrsUS$364.02k0.020%
$ 387.1k
Charles Craik
Scientific Advisorno datakeine Datenkeine Daten
Mark Gallop
Scientific Advisorno datakeine Datenkeine Daten
Wayne Lencer
Clinical Advisorno datakeine Datenkeine Daten
Aida Habtezion
Clinical Advisorno datakeine Datenkeine Daten
Ellen Scherl
Clinical Advisorno datakeine Datenkeine Daten
Bryan Giraudo
Independent Director6.1yrsUS$356.52k0.031%
$ 580.7k

9.4yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: PTGXDie Vorstandsmitglieder gelten als erfahren (9.4 Jahre durchschnittliche Amtszeit).